Change of Adviser
Updated : 07:07
26 June 2020
SkinBioTherapeutics plc
Change of Adviser
SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that Cenkos Securities plc has been appointed with immediate effect as the Company's Nominated Adviser and Sole Broker.
SkinBioTherapeutics plc | Tel: +44 (0) 161 468 2760 |
Stuart Ashman, CEO | |
Doug Quinn, CFO | |
Cenkos Securities plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7397 8900 |
Giles Balleny, Max Gould (Corporate Finance) | |
Michael Johnson (Sales)
| |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis | SkinBio@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.